Would you consider using checkpoint inhibitor therapy as an alternative to adjuvant mFOLFIRINOX in a patient with a very high risk resected pancreatic adenocarcinoma (poorly differentiated, N2 disease) and Lynch syndrome?

My inclination would be to offer standard of care modified adjuvant folfirinox and reserve pembro for documented recurrence. However, one could not criticize the use of pembro as adjuvant even with lack of proof in this setting. Also, if initiated, how long would you treat?